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Sarcoma is one of the most severe forms of pediatric cancer and current
therapies-chemotherapy and surgery- fail to eradicate the disease in half of patients.
Preclinical studies combining new therapeutic approaches can be useful to design
better therapies. On one hand, it is known that CXCR4 expression is implicated in
rhabdomyosarcoma progression, so we analyzed relapses and chemotherapy-resistant
rhabdomyosarcoma tumors from pediatric patients and found that they had
particularly high levels of CXCR4 expression. Moreover, in assays in vitro, anti-CXCR4
blocking antibody (MDX1338) efficiently reduced migration and invasion of alveolar
rhabdomyosarcoma RH30 cells. On the other hand, activated and expanded natural
killer (NKAE) cell therapy showed high cytotoxicity against sarcoma cells in vitro and
completely inhibited RH30 tumor implantation in vivo. Only the combination of MDX1338
and NKAE treatments completely suppressed metastasis in mice. In this study, we
propose a novel therapeutic approach based on anti-CXCR4 blocking antibody in
combination with NKAE cell therapy to prevent rhabdomyosarcoma tumor implantation
and lung metastasis. These results provide the first evidence for the efficacy of this
combined immunotherapy for preventing sarcoma disease dissemination.
Keywords: sarcoma, metastasis, chemokine C-X-C receptor 4 (CXCR4), therapeutic antibody, activated and
expanded natural killer (NKAE) cells, immunotherapy
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INTRODUCTION
Sarcomas principally affect children and young adults. Almost
half the children with solid tumors, such as rhabdomyosarcoma,
osteosarcoma and Ewing sarcoma, have progressive disease
despite aggressive treatment. The prognosis is particularly poor
for patients with metastatic disease, in at least two thirds of
whom the disease progresses (1–3). New therapeutic approaches
bypassing the cellular mechanisms of drug resistance are
therefore urgently required, particularly for patients with high-
risk features.
Chemokines interacting with the chemokine receptors
expressed by metastasizing tumor cells play a crucial role in
directing the migrating cells to secondary organs. This is well
documented for the chemokine CXCL12 and CXC chemokine
receptor 4 (CXCR4). Müller et al. discovered a CXCL12–
CXCR4 homing axis in cancer metastasis and demonstrated the
preferential migration of CXCR4-expressing breast cancer cells
toward protein extracts from the lung, which has high levels of
CXCL12 expression (4).
CXCL12 binding to CXCR4 stimulates intracellular calcium
flux, activates the AKT and ERK signaling pathways, and
upregulates the formation of focal adhesions, ultimately
increasing migration along gradients of locally expressed and
secreted chemokines (5). It also leads to the transcription
of genes promoting cell survival and proliferation. CXCR4
is found in various tissues and is predominantly expressed
on hematopoietic cells, including B and T cells, monocytes,
macrophages, natural killer (NK) and dendritic cells, and on
CD34+ bone marrow progenitor cells (6). CXCR4 is also weakly
expressed on endothelial and epithelial cells, astrocytes and
neurons (7, 8).
Khune et al. (Bristol-Myers Squibb) recently developed a fully
human monoclonal antibody (mAb), MDX1338/ulocuplumab,
specific for human CXCR4 (9). MDX1338 is a high-affinity
mAb that blocks CXCL12 binding to CXCR4, thereby inhibiting
the cell proliferation and migration promoted by this binding.
MDX1338 treatment has been shown to induce apoptosis in vitro
and anti-tumor activity in vivo in hematologic cancers.MDX1338
is an IgG4 isotype mAb. It does not, therefore, mediate antibody-
dependent cellular cytotoxicity (ADCC). Its pro-apoptotic effect
is associated with the production of reactive oxygen species and
does not require caspase activation, as described in a chronic
lymphocytic leukemia model (10).
Immune cells are known to recognize and kill tumor cells,
suggesting that they could be used in anticancer treatment.
NK cells kill cancer stem cells and genotoxically altered cells
with a high degree of precision but are tolerant to healthy
cells. These properties suggest that they might make good
therapeutic effectors for all cancer forms, including metastases
(11). Fujisaki et al. (12) and Imai and Iwamoto (13) reported
that the K562 leukemia cell line genetically modified to express
membrane-bound interleukin (IL)-15 and 4.1-BB ligand (K562-
mb15-41BBL) specifically activates human NK cells, driving
them into the cell cycle to generate highly cytotoxic NK cells.
Furthermore, the K562-mb15-41BBL stimulation method has
already been scaled up to large-scale clinical-grade conditions in
accordance with good clinical manufacturing practice guidelines,
for the production of large numbers of highly cytotoxic NKAE
cells, and FDA-approved clinical trials are already underway in
patients with hematologic cancers and childhood solid tumors.
Our team has leaded five clinical trials using adoptive
NK cell immunotherapy in patients with pediatric refractory
solid tumors (NCT01337544), relapsed or refractory acute
leukemia/lymphoma (NCT01944982 and NCT02074657),
acute myeloid leukemia (NCT02763475) or multiple myeloma
(NCT02481934). Our results show it is a promising and feasible
therapy (14–16). Based on our experience with NKAE cell
therapy, we hypothesized that the anti-metastatic MDX1338
mAb and cytotoxic NK cell therapy would have complementary
effects, thereby increasing the efficacy of the therapeutic strategy.
We analyzed CXCR4 expression in tumor samples from
pediatric rhabdomyosarcoma patients. We present preclinical
data showing the ability of NKAE cell therapy to kill sarcoma
cells and of MDX1338 mAb to inhibit the migration and
invasion of CXCR4+ sarcoma cells in vitro. We also used an
orthotopic model of alveolar rhabdomyosarcoma to evaluate
the complementary antitumoral and antimetastatic effects of
combined NKAE+MDX1338 immunotherapy in vivo.
MATERIALS AND METHODS
Determination of CXCR4 Expression on
Patients’ Samples by
Immunohistochemistry
Human samples were obtained after informed patient consent
in accordance with the Helsinki Declaration. Research was
approved by the La Paz Hospital Ethics Committee (PI-2295).
For tumor CXCR4 immunohistochemistry, formalin-fixed,
paraffin-embedded tumor slides were deparaffinized, hydrated,
stained using anti human CXCR4 mAb (dilution 1:10; clone
44716; R&D systems), visualization system EnVision FLEX+
(mouse, high pH, Agilent) and hematoxylin counterstained.
Specificity of the antibody was confirmed by immunostaining of
tonsil tissue. The percentage of CXCR4+ tumor cells was assigned
a score between 0 and 5, and the staining intensity a score
between 0 and 3. These 2 values were added. Both cytoplasmic
and nuclear staining were assessed and equally weighted to
produce the final staining score.
Cell Culture
143B (CRL-8303), MG-63 (CRL-1427) and A673 (CRL1598) cell
lines were from the American Type Culture Collection. RH30
(ACC-489) was from the Leibniz-Institut DSMZ. A4573 and
CW9019 were kind gifts from Dr. Javier Alonso (Institute of
Health Carlos III) and Dr. Josep Roma (Vall d’Hebron Research
Institute), respectively.
Bioluminescent RH30 cells (RH30-GFP-Luc) were generated
by infection with a recombinant lentivirus encoding green
fluorescent protein (GFP) and firefly luciferase (Luc) under
EF1a promoter and with Neomycin marker (Amsbio). Infected
cells expressing high GFP levels were isolated by fluorescence
activated cell sorting, cloned, expanded, and used for in vivo
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bioluminescence assays. RH30-GFP-Luc cell growth kinetics
was similar to parental RH30 cells and they retained surface
CXCR4 expression.
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Lonza) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Gibco), 2mM L-glutamine, 50 U/ml
penicillin, and 50µg/ml streptomycin (complete medium).
NK Cells Activation and Expansion
Peripheral blood mononuclear cells (PBMCs) from healthy
donors were isolated by centrifugation over a density gradient
(Ficoll-Paque, GE Healthcare) (400 g, 30 min).
The genetically modified K562-mbIL15-41BBL cell line,
kindly provided by Professor D. Campana (National University
of Singapore) was irradiated with 100 Gy.
NKAE cells were obtained by co-culturing donor’s PBMCs
with irradiated K562-mb15-41BBL cells in a 1:1.5 ratio plus
100 U/ml of IL-2 (Miltenyi) over 14–21 days in stem cell
growth medium (SCGM, Cellgenix) supplemented with 10%
human AB serum (Sigma). Fresh medium was added every
2–3 days to a final concentration of 1 × 106 cells/ml.
Percentage and phenotype of NK cells (CD3−, CD56+), T
cells (CD3+, CD56−) and NKT cells (CD3+, CD56+) was
weekly monitored by flow cytometry (Navios, Beckman Coulter)
(Supplementary Figure 1). A list of labeled antibodies used in
this study is provided in Supplementary Table 1.
Determination of CXCR4 Expression on
Sarcoma Cell Lines by Flow Cytometry and
qRT-PCR
For staining, 2 × 105 cells/well were centrifuged in V-bottom
96-well plates and washed with phosphate-buffered saline (PBS,
Lonza) containing 0.5% bovine serum albumin (Lonza), 1%
FBS and 0.1% sodium azide. Non-specific binding was blocked
by pre-incubating the cells with 40µg/ml rat IgG (Sigma; 100
µl final volume, 20min, 4◦C). Cells were incubated with anti
CXCR4-APC mAb (BD Pharmingen; clone 12G5) or isotype
matched mAb (30min, 4◦C). Samples were analyzed on a Navios
cytometer (Beckman Coulter).
For qRT-PCR, cell culture RNA was obtained using
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
protocol. The relative expression level of mRNA encoding
human CXCR4 was determined by quantitative RT-PCR
using GUS gene expression as internal control. cDNA was
synthesized from 1 µg of total RNA with the Superscript
IV First-Strand Synthesis System (Invitrogen). The cDNA
was amplified in duplicate with primers for human CXCR4




from Sigma). Amplification (1 cycle: 50◦C for 2min, 95◦C for
10min; 50 cycles: 95◦C for 15 s, 60◦C for 1min) was monitored
using the Roche LightCycler 480. Relative expression was
analyzed using 2−1CT method, where 1CT = (Ct gene of
interest- Ct internal control).
Cell-Mediated Cytotoxicity Assays
NKAE and RH30-GFP-Luc target cells were co-cultured (4 h)
at indicated ratios in DMEM- 10% FBS, then stained with 7-
AAD (10min, 4◦C) and analyzed by flow cytometry. Gating
on 7-AAD+ cells within the GFP+ population indicated the
proportion of dead target cells. Specific killing was calculated
as 100 × [(% dead target cells in sample–% spontaneous dead
target cells)/(100–% spontaneous dead target cells)]. Target cells
incubated without effector cells were used to assess spontaneous
cell death. In Supplementary Figure 2, RH30-GFP-Luc cells
were pre-incubated with MDX1338 or isotype IgG4 control mAb
(30min, 100µg/ml) prior to the assay.
Cell Migration and Invasion Assays
Cells were incubated in starving buffer (DMEM-1% FBS) for
24 h. Next, 2 × 105 cells were suspended in 80 µl of migration
buffer (DMEM-1% human serum albumin, Grifols) and placed
in the upper compartment of 96-well transwell plates (8.0µm
pore size, Neuroprobe). The lower compartment was filled with
300 µl of: migration buffer alone (unconditioned medium),
migration buffer with 100 ng/ml CXCL12 (R&D systems) or
migration buffer with 10% FBS. In invasion assays, the upper
compartment of the membrane was coated with 20 µl of 0.2
mg/ml Matrigel (Corning).
After 48 h of incubation to allow cells to migrate/invade
through the membrane, the cells remaining on the upper face of
the membrane were removed using a cotton wool swab, while
the cells on the lower side of the membrane were fixed with
methanol and stained with crystal violet. After washing with PBS,
the number of migrating/invading cells was determined using a
Carl Zeiss Axiovert 200 microscope. Four fields per well were
counted at 200x.
For migration/invasion neutralization experiments, 105 RH30
cells were mixed with the indicated final concentration of anti
CXCR4 MDX1338 mAb or control IgG4 mAb in a final volume
of 90 µl of migration buffer and proceeded as above indicated.
In Supplementary Figure 2, 500.000 NKAE cells (effector:target
ratio, E:T= 5:1) were also added in the upper well.
Xenograft Assays
NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Charles River
Laboratories) were maintained in the Alberto Sols Biomedical
Research Institute animal facility. All procedures were approved
by Comunidad de Madrid Animal Protection Area (PROEX
220/16) and CSIC Ethics Committee.
For the in vivo metastasis model, 6 weeks of age female mice
were inoculated intravenously (i.v.) with 0.5 × 106 RH30-GFP-
Luc cells on day 0. Five treatment groups were established (5
mice/group): untreated; isotype control IgG4 mAb; anti CXCR4
MDX1338 mAb; NKAE cells; and MDX1338 + NKAE cells.
Antibodies were inoculated intraperitoneally (i.p.), 15 mg/kg,
twice a week for 3 weeks. NKAE cells were administered i.v., 5
x 106 cells/mouse, once a week for three weeks.
Luminescent tumors were monitored weekly for 35 days.
Briefly, D-luciferin (150 mg/kg; Perkin Elmer) was administered
i.p. 10min before analysis. During imaging, mice were
anesthetized with isoflurane in a lightproof chamber using
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a IVIS-Lumina II (Caliper Lifesciences). Exposure time was
180 s. Living Image v4.5.2 (Perkin Elmer) was used to quantify
the data and produce pseudocolor images.
Histology and Identification of Lung
Micrometastases in Mice
Mice dissected organs were fixed overnight in 4%
paraformaldehyde (pH 7.4), washed in PBS, paraffin-embedded
and cut (3 µm).
The presence of RH30 cells in the lungs was studied
by immune staining using anti-human CXCR4 antibody
(R&D, clone 44716, dilution 1:50), visualization system
EnVision FLEX+ (mouse, high pH; Agilent) and
hematoxilin/eosin counterstained.
For in situ hybridization, antigen retrieval was first performed
with low pH buffer (RiboCC, Roche) and protease III (Roche).
Slides were then incubated with the Alu positive control
probe II (Ventana, Roche 05272041001). Three stringency
washes were performed and slides were incubated with rabbit
anti-DNP anti serum. For visualization, OmniRabbit system
conjugated with horseradish peroxidase was used (Ventana,
Roche). Immunohistochemical reaction was developed using
silver as chromogen (Silver kit, Ventana, Roche) and nuclei were
counterstained with Carazzi’s hematoxylin.
All images were captured on a Carl Zeiss Lab.A1 microscope
with an AxioCam ERC5S digital camera (Carl Zeiss).
qRT-PCR and Quantification of Lung
Micrometastases in Mice
One third of mice dissected organs were used for total RNA
extraction using RNAeasy Mini kit (Qiagen) according to the
manufacturer’s protocol. The relative expression levels of mRNA
encoding human CXCR4 and human GUS were determined by
semi-quantitative RT-PCR with RH30 cells pellet as control of
100% human cells. cDNA synthesis and human CXCR4 and
human GUS amplification was performed as above indicated.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7
software. Statistical significance was established at p < 0.05 as
evaluated by unpaired Student’s t-test or ANOVA test. Results are
shown as mean± SEM, unless otherwise indicated.
RESULTS
CXCR4 Is More Strongly Expressed on
Relapsed Samples From Pediatric
Rhabdomyosarcoma Patients Than in
Diagnostic Samples
New treatment options are urgently required for patients
whose tumors do not respond to chemotherapy and for
relapses after surgery. We investigated the potential role of
CXCR4 in chemotherapy resistance and relapse, by performing
immunohistochemical analyses to evaluate CXCR4 expression
in rhabdomyosarcoma tumor samples. Patients’ characteristics
are listed in Supplementary Table 2. We analyzed 26 pediatric
rhabdomyosarcoma specimens archived in the biobank of La
Paz University Hospital from 2010 to 2017. These specimens
were taken from patients with a median age of 6.6 years (range:
0.2–14.1) and a median follow-up of 7.9 years (range: 0.6–
18.4). Seventeen of the specimens were obtained at diagnosis,
five are refractory samples collected after chemotherapy and
four specimens corresponded to relapses. As recent studies have
reported CXCR4 to be expressed in the nucleus in some cancers
(17, 18), we performed both cytoplasmic and nuclear staining,
with equal weighting given to the two compartments during the
analysis. Cytoplasmic staining for CXCR4 was observed on 68%
of the specimens in our series and nuclear staining was observed
in 15% (Figure 1A).
For diagnostic samples, no difference in CXCR4
expression was observed between embryonal and alveolar
rhabdomyosarcomas or between specimens from localized
tumors and those from primary tumors that already had
metastasized (Figure 1B). A relationship was observed between
CXCR4 score and patient outcome, with higher CXCR4 median
score obtained for specimens from patients subsequently
suffering from relapses or dying from the disease (Figure 1C).
Moreover, a comparison of CXCR4 expression score
between diagnostic (2.8 ± 2.1) and relapsed/refractory (5.1 ±
2.9)specimens revealed a significant trend toward higher levels
of CXCR4 expression in relapse samples than in diagnostic
samples (Figure 1D).
The RH30 Alveolar Rhabdomyosarcoma
Cell Line Had the Highest Levels of CXCR4
Expression, Concomitant With Highest
Migration and Invasion Rates Toward
CXCL12
We analyzed the surface expression of CXCR4 on confluent
cultures of various sarcoma cell lines: RH30, CW9019, A4573,
A673, MG-63, and 143B. The proportion of CXCR4+ cells was
highest in RH30 cell cultures, in which CXCR4 expression was
detected on 98.6 ± 0.7% of the cells (Figure 2A). These results
were consistent with the analysis of CXCR4 mRNA levels by
RT-qPCR analysis. RH30 cultures displayed 1.38 ± 0.01 times
higher levels of CXCR4 than of a control gene expression (beta-
glucuronidase, GUS) (Figure 2B).
We evaluated the migration and invasion capacity of sarcoma
cell lines in Transwell assays, which are considered to provide
an in vitro indication of metastatic potential in vivo. Several
sarcoma cell lines migrated toward chemoattractant FBS and
displayed invasion capacity (Figure 2C), but only the RH30
cell line migrated and invaded specifically toward the CXCR4
ligand, CXCL12 (Figure 2D). The indices of RH30 migration
and invasion toward CXCL12 were 35.2 ± 8.3 and 104.0 ±
16.4, respectively.
NKAE Cells Were Highly Cytotoxic to RH30
Cells, and MDX1338 Efficiently Reduced
RH30 Cell Migration and Invasion Toward
CXCL12
NK cells play an important role in the natural control of tumor
cells. By co-culturing these cells with the genetically modified
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FIGURE 1 | CXCR4 expression on the tumors of rhabdomyosarcoma patients. (A) Representative staining corresponding to samples with negative (a), medium (b)
and high (c) levels of cytoplasmic CXCR4 expression. A specimen with a high level of nuclear CXCR4 staining is also shown (d). Scale bar = 10µm. N = 26.
(B) CXCR4 expression score plot for primary tumors at diagnosis where alveolar vs. embryonal rhabdomyosarcomas are compared and where localized vs. already
metastasized rhabdomyosarcomas are compared. (C) Primary tumors at diagnosis CXCR4 expression vs. outcome (disease relapse or patient’s death).
(D) Comparison of CXCR4 expression between specimens obtained at diagnosis and after chemotherapy (refractory) and during relapse. The values shown are the
median ± SD. Unpaired Student’s t-tests were performed. *p < 0.05.
cell line K562-mb15-41BBL, large numbers of activated NK cells
(NKAE cells) can be obtained from healthy donors.Wemeasured
the cytolytic effects of NKAE cells on RH30 sarcoma cells. NKAE
cells induced 21.9 ± 0.4% specific lysis of RH30 cells, at an
effector:target cell (E:T) ratio of 20:1 (Figure 3A). As expected,
MDX1338 had no significant effect on the observed cytotoxicity
(Supplementary Figure 2A). MDX1338 is a fully human IgG4
anti-CXCR4 mAb (9, 10), and would not, therefore, be expected
to induce ADCC (19).
The effect of MDX1338 on the CXCR4/CXCL12 axis was
assessed in RH30 cells, in migration, and invasion assays in vitro.
MDX1338 significantly decreased the migration of RH30 cells
toward CXCL12 and their invasion capacity: 54.4 ± 4.4 vs. 10.5
± 2.0 for migration and 199.1 ± 2.9 vs. 25.6 ± 1.9 for invasion
(Figure 3B). The combination of MDX1338 and NKAE cells
totally abolished the migration and invasion capacities of these
cells (Supplementary Figure 2B).
NKAE Cell Treatment Completely Inhibited
the Implantation of RH30 Tumor Cells
in vivo
We assessed the antitumor potential of MDX1338 and NKAE cell
therapies, by generating an in vivo model of metastatic sarcoma,
using CXCR4+ RH30 cells, which grow as peritoneal xenografts
when implanted in immunodeficient NSG mice. Mice were
inoculated intravenously with RH30-GFP-Luc cells (day 0). They
then received one of the following treatments: MDX1338 mAb,
isotype control IgG4 mAb, NKAE cells or combined MDX1338-
NKAE cells treatment (Figure 4A). The size of the developing
tumors was assessed by measuring the luminescent signal, until
day 36, when the mice were killed. NKAE cell therapy alone was
sufficient to prevent the intraperitoneal implantation of RH30
tumors entirely (Figure 4B). Mice treated with MDX1338 mAb
alone developed intraperitoneal tumors slightly smaller than
those of the control mice, whereas a control IgG4 mAb had no
significant effect.
Rhabdomyosarcoma Lung
Micrometastases Were Abolished by
MDX1338 + NKAE Cell Treatment in an
in vivo Model
The primary peritoneal RH30 tumors were easy to monitor
with the luminescent detection system, but the sensitivity of this
approach was too low to determine whether RH30 GFP+ Luc+
micrometastases were present in distal organs. We therefore used
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FIGURE 2 | Analysis of CXCR4 expression, and of the migration and invasion capacity of different sarcoma cell lines. (A,B) CXCR4 expression was strongest in the
RH30 alveolar rhabdomyosarcoma cell line. CXCR4 expression by two rhabdomyosarcoma cell lines (RH30 and CW9019), two Ewing’s sarcoma cell lines (A4573 and
A673) and two osteosarcoma cell lines (MG-63 and 143B) was analyzed by flow cytometry (A) and by RT-qPCR (B). N = 3. (C,D) RH30 cells migrate and invade
along a gradient toward CXCL12 chemokine, CXCR4 specific ligand. Their ability to migrate toward FBS (C) or CXCL12 (D) was assessed in Transwell assays, with
membranes with 8µm pores. Invasion capacity was measured under the same conditions, with Matrigel-coated Transwell membranes. Each condition was
performed in duplicated wells. Representative results of one experiment out of three performed.
RT-qPCR to assess the presence of human cells by amplifying
both human GUS and human CXCR4 cDNAs from the lungs,
liver, spleen and bone marrow of the mice. Human gene
expression was detected only in the lungs, indicating the presence
of RH30 cells in this organ.
NKAE cell treatment alone was insufficient to prevent RH30
lung micrometastases. The relative level of expression for
human GUS was 14.5 × 10−3 ± 5.4 × 10−3 in untreated
mice and 8.3 × 10−3 ± 2.7 × 10−3 in NKAE-treated
mice. For human CXCR4, relative expression levels were
11.4 × 10−3 ± 4.7 × 10−3 in untreated mice and 10.7
× 10−3 ± 4.1 × 10−3 in NKAE-treated mice. MDX1338
treatment alone significantly decreased the formation of
micrometastases, but only the combination of MDX1338
and NKAE treatments led to undetectable levels of both
human GUS and CXCR4 gene expression in the mouse
lungs analyzed (Figure 5A). We have performed a RT-
PCR to confirm that the human cells present in the mice
lungs were RH30 cells. RH30 cells have t(2,13) chromosomal
translocation resulting in PAX3-FOXO1 fusion protein (20). We
detected specific chimeric gene transcript PAX3-FOXO1 (21), in
untreated, IgG4-, MDX1338- and NKAE-treated mice, whereas
we could not detect it in NKAE+MDX1338-treated mice lungs
(Supplementary Figure 3).
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FIGURE 3 | In vitro NKAE-mediated cytotoxicity and MDX1338-mediated inhibition of the migration and invasion capacity of rhabdomyosarcoma cells. (A) NKAE cells
were highly cytotoxic to RH30 cells. Specific lysis was determined at the indicated NKAE:RH30 E:T ratios. (B) MDX1338 efficiently decreased the migration and
invasion of RH30 cells toward CXCL12. RH30 cell migration was assessed with Transwell plates. Invasion capacity was measured under the same conditions, with
Matrigel-coated Transwell membranes. Every condition was performed in duplicates. One representative experiment is shown. N = 3. One-way ANOVA test.
*p < 0.05, ***p < 0.0001.
FIGURE 4 | Inhibition of tumor implantation in vivo by NKAE cells. (A) Administration schedule for the antibody and NKAE cells in NSG mice bearing RH30 GFP+
Luc+ tumor cells injected intravenously. Five treatment arms were established: untreated; IgG4; MDX1338; NKAE; MDX1338+NKAE (5 mice/group). Two-way ANOVA
test. Mice received three doses of NKAE and six doses of mAb. Luminiscent tumors were monitored for 35 days. (B) The NKAE treatment completely prevented the
peritoneal implantation of RH30 tumors in mice. ***p < 0.0001.
For further confirmation of the presence of RH30
micrometastases, lung samples were stained with an Alu
sequence probe or the anti-human CXCR4 mAb. Human cell
aggregates were found in the lungs of untreated mice for both
staining procedures (Figure 5B).
DISCUSSION
Sarcomas, such as Ewing’s sarcoma, osteosarcoma, and soft
tissue sarcomas like rhabdomyosarcomas, form a group of
relatively rare mesenchyme-derived tumors (22). They account
for only a small percentage of human cancers overall, but are
the second most prevalent solid tumor in children. Despite
advances in adjuvant chemotherapy and surgical wide resection,
prognosis remains poor, mostly due to the high frequency of lung
metastasis, the leading cause of death in these patients.
Chemokines and their interaction with their receptors have
been shown to play a fundamental role in the mechanisms of
cancer development and metastasis (23). The expression levels
of chemokines and their receptors are altered in malignant
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FIGURE 5 | Abolition of the formation of lung micrometastases of rhabdomyosarcoma by MDX1338. (A) NKAE-treated mice develop RH30 micrometastases in the
lung, but this is entirely prevented by the combination of MDX1338 and NKAE. Micrometastases were detected and quantified by RT-qPCR with a human GUS- or
human CXCR4-specific probe. Each sample was analyzed in duplicates, 5 mice per group were analyzed. Two-way ANOVA test. (B) The presenceof
rhabdomyosarcoma micrometastases was confirmed by histological methods. Lung micrometastases in untreated mice were identified by Alu sequence hybridization
(a) and CXCR4-specific mAb staining (b). Scale bar = 20µm. *p < 0.05, ***p < 0.001.
cells. This has been shown for CXCR4, the chemokine receptor
most frequently overexpressed in tumor cells. The interaction of
CXCR4 with its ligand, CXCL12, activates a cascade of cellular
signaling promoting the survival, proliferation, adhesion, and
migration of the CXCR4-expressing tumor cells. This may lead
to a relapse of the primary tumor, and it increases the likelihood
of distant metastases in organs in which the ligand is secreted,
such as the bone marrow and lungs in particular (5, 24).
Aberrant CXCR4 expression has been observed in more
than 23 human cancers. The prognostic significance of CXCR4
has been studied in detail in patients with bone and soft
tissue sarcomas (25–30). In a recent meta-analysis of 12 studies
including a total of 997 sarcoma patients, CXCR4 expression
was found to be significantly associated with poor overall
survival, higher rates of metastasis and higher tumor stage
(18). In our cohort of pediatric rhabdomyosarcoma patients, we
found a correlation between higher levels of CXCR4 expression
at diagnosis and relapse. Tumor-initiating cells (TICs) are a
subpopulation of chemoresistant tumor cells that have been
shown to cause tumor recurrence and metastasis. One of the
hallmarks of these cells is an upregulation of CXCR4 (24).
Consistent with this finding, we observed that the tumors
that continued to grow after chemotherapy or that relapsed
after surgery and chemotherapy were those with the highest
CXCR4 levels (Figure 1C). The elimination of TICs is therefore
a priority in the development of new modes of treatments.
These cells are the target of our combined anti-CXCR4 mAb and
NKAE treatment.
The hijacking of the CXCL12/CXCR4 signaling pathways by
tumor cells for the purposes of metastasis and protection from
apoptosis rapidly identified the blockade of this axis as a potential
treatment target for cancer. A pioneering study by Müller et al.
(4) demonstrated the in vivo relevance of CXCR4 as a target
for cancer therapy, linking the expression of CXCR4 in breast
carcinomas with their ability to generate regional lymph node
and lung metastases. These data were supported by experiments
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in which a neutralizing anti-human CXCR4 antibody (murine
mAb, clone 44717.111) significantly decreased the frequency
of lung, inguinal and axillary lymph node metastases. Similar
results were subsequently obtained with another murine anti-
human CXCR4 antibody (clone 12G5) (31–33). In a human
intratibial osteosarcoma xenograft model, the 12G5 mAb
reduced metastatic spread to the lung (34). Interestingly, in a
rhabdomyosarcoma xenograft model, a thirdmurine anti CXCR4
mAb (clone CF172) showed some resistance to lymph node
metastasis while had little effect on the primary tumor volume
(35). Consistent with these previous findings, our results for
MDX1338, a fully human mAb blocking the CXCR4/CXCL12
axis, show that this mAb can efficiently decrease the migration
and invasion indices of metastatic RH30 rhabdomyosarcoma
cells in vitro. Similarly, in vivo, the combination ofMDX1338 and
NKAE treatments not only abolished implantation of the RH30
tumor, but also its ability to disseminate, thereby preventing the
formation of lung micrometastases.
In physiological non-pathological conditions, CXCL12, and
CXCR4 are important for the development of the central
nervous system, the heart and the immune system (36, 37).
It will therefore be essential to monitor potential adverse
effects very carefuly in any therapeutic approach involving a
blockade of this axis. Plerixafor, a small-molecule antagonist of
CXCR4, is widely used to mobilize hematopoietic stem cells
for autologous transplantation in non-Hodgkin’s lymphoma
and multiple myeloma (38). No serious adverse effects related
to CXCL12/CXCR4 blockade have been reported following
the administration of plerixafor in patients. MDX1338 has
already been tested in phase I and II clinical trials for
the treatment of Waldenstrom’s macroglobulinemia, leukemia,
solid tumors, acute myelogenous leukemia, diffuse large B-cell
leukemia, chronic lymphocytic leukemia, follicular lymphoma,
and multiple myeloma. Its antitumor effect is mediated by a
mobilization of myeloma cells from the bone marrow or by
the direct induction of apoptosis, rather than through cellular
cytotoxicity, because it is an IgG4 isotype antibody (9, 10, 39).
No serious adverse effects due to CXCL12/CXCR4 blockade by
MDX1338 have been reported in these trials, either.
In this study, we propose a novel immunotherapy for the
treatment of sarcomas. This treatment combines the ability of
NK cells to eliminate tumor cells without prior sensitization with
anti-CXCR4 treatment to decrease the incidence of metastasis.
We previously showed that osteosarcoma cells are susceptible
to NKAE lysis both in vivo and in vitro, and that this cytolytic
activity is dependent on interactions between the NKG2D
receptor and its ligands (40). The NKAE cells targeted sarcoma
cells, including the TICs compartment. We therefore decided
to test the potentially additive effects of MDX1338 and NKAE
cell therapy for the treatment of rhabdomyosarcoma. We show
here that a combination of NKAE cells and MDX1338 efficiently
inhibits rhabdomyosarcoma cell invasion, tumor implantation
and metastasis.
As mentioned, NK constitutively express CXCR4 and so do
NKAE cells (41). The effect of anti CXCR4 on NKAE should,
therefore, be taken into account in the proposed combined
therapy. In mice, the administration of the CXCR4 antagonist,
AMD-3100/plerixafor to C57BL/6mice induced strong reduction
of NK cells in the bone marrow and increased their number
in blood and spleen (42). These results are transposable to our
model, since the CXCR4 and CXCL12 genes are remarkably
conserved across diverse species. The human and murine
CXCL12 differs by one amino acid and is cross reactive (43).
Similarly, in a rhesus macaque model, AMD-3100 treatment led
to mobilization of NK, together with B and T cell subpopulations
into the peripheral blood (44). In our model, we hypothesize
that MDX1338 blocks not only metastatic CXCR4+ sarcoma cells
migration to the lungs, but also blocks therapeutic NKAE cells
homing to the bone marrow and favors their permanence in
the blood stream, where they are more likely to find and kill
metastatic neoplastic cells.
Clinical trials of the adoptive transfer of NK cells have been
published. These trials made use of resting NK cells (45, 46)
or NK cells cultured with IL-2 (47–49). The use of activated
and expanded NK cells cocultured with human-derived antigen-
presenting cells, as proposed here, is an emerging alternative (14,
15, 50, 51). Our and others’ results indicate that both autologous
and haploidentical NKAE cell therapies are safe, with no serious
adverse effects, and feasible for use in the treatment of various
types of cancer.
The results presented here demonstrate that combined
treatment with the anti-CXCR4 mAb MDX1338 and NKAE
cell therapy prevents rhabdomyosarcoma cells from migrating,
invading, tumor implantation and the formation of lung
metastases. They support the establishment of a clinical trial to
evaluate this pioneering combined treatment scheme. Previous
studies have indicated that both these treatments are well
tolerated, at least when used separately, so the translation of
this approach into clinical practice should be straightforward.
This is an important point given the urgent need for new
strategies to improve treatment efficacy in sarcoma patients with
metastatic disease.
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